论文部分内容阅读
目的探讨氨溴索联合阿奇霉素治疗儿童支原体肺炎的临床效果。方法选取2014年2月—2016年2月都安瑶族自治县妇幼保健院收治的支原体肺炎患儿84例,随机分为对照组和治疗组,各42例。对照组患儿在常规治疗方案基础上给予静脉滴注阿奇霉素治疗,治疗组患儿在对照组基础上给予静脉滴注氨溴索注射液治疗。比较两组患儿治疗效果、治疗前后肺功能指标[用力肺活量占预计值的百分比(FVC%)、第1秒用力呼气末容积占预计值的百分比(FEV_1%)、呼气峰流速占预计值的百分比(PEF%)]、体温恢复正常时间、呼吸功能及相关指标恢复正常时间、住院时间及药物不良反应发生情况。结果治疗组患儿治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患儿PEF%、FEV_1%、FVC%比较,差异无统计学意义(P>0.05);治疗后治疗组患儿PEF%、FEV_1%、FVC%高于对照组,差异有统计学意义(P<0.05)。治疗组患儿体温恢复正常时间、相关指标恢复时间、住院时间短于对照组,差异有统计学意义(P<0.05)。两组患儿不良反应发生率比较,差异有统计学意义(P<0.05)。结论氨溴索联合阿奇霉素治疗儿童支原体肺炎的临床效果确切,可有效改善患儿肺功能指标和临床症状,且不良反应少。
Objective To investigate the clinical efficacy of ambroxol combined with ambroxol in children with mycoplasma pneumonia. Methods Eighty-four children with Mycoplasmal pneumonia admitted to the Maternal and Child Health Hospital of Du’an Yao Autonomous County from February 2014 to February 2016 were randomly divided into control group and treatment group, with 42 cases in each group. Patients in the control group were treated with intravenous azithromycin on the basis of routine treatment. The children in the treatment group were given intravenous infusion of ambroxol injection on the basis of the control group. The therapeutic effect of two groups of children was compared before and after treatment, pulmonary function indicators [FVC% of forced vital capacity (FVC%), forced end-expiratory volume of 1 second as a percentage of expected value (FEV_1%), peak expiratory flow rate Percentage of value (PEF%)], body temperature returned to normal time, respiratory function and related indicators returned to normal time, hospital stay and adverse drug reactions. Results The total effective rate of treatment group was higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference in PEF%, FEV_1% and FVC% between the two groups before treatment (P> 0.05). After treatment, PEF%, FEV_1% and FVC% of children in treatment group were higher than those in control group Significance (P <0.05). The recovery time of body temperature in the treatment group was shorter than that of the control group (P <0.05). Two groups of children with adverse reactions, the difference was statistically significant (P <0.05). Conclusion Ambroxol combined with azithromycin in children with mycoplasma pneumonia clinical effect is exact, can effectively improve children with lung function indicators and clinical symptoms, and less adverse reactions.